Fig. 2: Eliglustat ameliorates 5TGM1-GFP MM cell-induced bone disease. | Nature Communications

Fig. 2: Eliglustat ameliorates 5TGM1-GFP MM cell-induced bone disease.

From: Modulating glycosphingolipid metabolism and autophagy improves outcomes in pre-clinical models of myeloma bone disease

Fig. 2

5TGM1-GFP MM cells were injected to 8-week-old female C57BL/KaLwRijHsd mice to generate the MM model. Eliglustat chow was administered from day 4 post tumor injection (until day 23). a Representative micro-CT reconstruction images of tibiae trabecular bones from naive control (Ctr, n = 5 biologically independent animals), MM mice with normal chow (MM, n = 7 biologically independent animals), or MM mice with eliglustat chow (MM + Elig, n = 7 biologically independent animals). b–h Tibiae trabecular bone parameters were assessed: BV/TV, BS, Tb.N, Conn.D, Tb.Th, BS/BV, and Tb.Sp (Ctr, n = 5; MM, n = 7, and MM + Elig, n = 7 biologically independent animals). i, j Tibiae cortical bone reconstruction (i) and the number of cortical bone lesions (j) (Ctr, n = 5; MM, n = 7, and MM + Elig, n = 7 biologically independent animals). k–n Representative TRAP/0.2% methyl green staining showing red OCs of tibial histological sections with original magnification ×40 (k) and the quantification of OCs with Oc.S/BS, N.Oc/T.Ar, and N.Oc/B.Pm (l–n) (Ctr, n = 5; MM, n = 7, and MM + Elig, n = 7 biologically independent animals). The result is representative of two independent experiments. Data are presented as mean values ± SEM. Exact p-values are depicted in the figure. Statistical analysis was performed using One-way ANOVA. Source data are provided as a Source Data file.

Back to article page